Emma Walmsley was appointed CEO of GSK, a global biopharma company in 2017. Previously, she was CEO of GSK Consumer Healthcare and then Chaired this Joint Venture listed as Haleon in July 2022, the largest demerger in Europe for 20 years.
GSK is a world leader in the prevention and treatment of infectious diseases (including HIV), Respiratory, Immunology and Oncology. The company has begun a new chapter of vaccine and medicine innovation and competitive performance. GSK aims to impact the health of 2.5 billion people in the decade ahead and in 2022 was placed first in the Global Access to Medicines Index for the eighth consecutive time.
Prior to GSK, Emma spent 17 years at L’Oreal, in Paris, London, New York and Shanghai. She is a Board Director of Microsoft, a member of the Stanford Medicine Board of Fellows, the US Business Council Executive Committee and has been a business advisor to three UK Prime Ministers. Emma is the first woman to run a major global pharmaceutical company, ranked number 1 three times in Fortune Magazine’s “Most Powerful International Women” and number 14 in Forbes’ Global Power Women in 2022. She holds an MA in Classics and Modern Languages from Oxford University.
